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13.05.003Abstract Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythe-
matosus (SLE), which is associated with signiﬁcant morbidity and mortality of SLE patients. The
pathogenesis of LN involves multiple factors, including genetic predisposition, epigenetic regulation
and environmental interaction. Over the last decade, omics-based techniques have been extensively
utilized for biomarker screening and a wide variety of variations which are associated with SLE and
LN have been identiﬁed at the levels of genomics, transcriptomics and proteomics. These studies
and discoveries have expanded our understanding of the molecular basis of the disease and are
important for identiﬁcation of potential therapeutic targets for disease prediction and early treat-
ment. In this review, we summarize some of the recent studies targeted at the identiﬁcation of
LN-associated biomarkers using genomics and proteomic approaches.Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
disease characterized by production of autoantibodies against
a broad range of self-antigens including DNA, RNA, histones
and other nuclear components. In most patients, vital organs
and tissues are often implicated, including kidney, brain, car-
diovascular, joint and skin. Lupus nephritis (LN) is a common
and serious complication in SLE and is associated with signif-
icant mortality and morbidity of SLE patients. Generally, 74%
of lupus patients will develop clinically relevant nephritis atdu (Li Q-Z).
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of LN is a complex process, involving deposition of autoanti-
bodies in the glomerulus, activation of complement and mac-
rophages, cell proliferation, production of extracellular
matrix proteins, pro-inﬂammatory cytokines and chemokines,
which are then linked through multiple mechanisms to cause
tubular damage, tubulointerstitial inﬂammation and ﬁbrosis.
So far, LN remains a major challenge and continues to be
one of the most severe manifestations of SLE [2]. The medical
therapy for LN depends on the severity of the disease. Thus,
ﬁnding reliable biomarkers for LN will help to evaluate disease
activity, identify patients at risk for kidney damage and facil-
itate early diagnosis and intervention to improve favorable
outcomes [3].
Multiple lines of evidence have supported a genetic etiology
in SLE and LN. Linkage analysis and Genome-wide associa-
tion studies (GWAS) have been used for screening lupus sus-
ceptibility and analyses of common genetic variants in lupus
have revealed a number of susceptibility loci [4,5]. Nonetheless,cademy of Sciences and Genetics Society of China. Production and hosting
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of disease heritability [6,7]. Other heritable factors of complex
human disease may broadly reside in epigenetic mechanisms.
Epigenetics refers to heritable modiﬁcations that regulate gene
expression without causing DNA sequence changes. Common
epigenetic mechanisms include DNA methylation, histone
modiﬁcation and regulation by microRNAs (miRNAs). The
variations at the genetic and epigenetic level may be reﬂected
by the different level of protein biomarkers such as autoanti-
bodies and cytokines in serum and urine of LN patients. In this
paper, we will brieﬂy review recent discoveries of genetic and
proteomic biomarkers, which are associated with susceptibility
and pathogenesis of LN.Genes and genetic variations associated with LN
SLE susceptibility is a complex trait. Some linkage studies
have assessed many candidate genes for potential roles in pre-
disposing to SLE. A comparative study of relative risk of dis-
ease in siblings of patients with that of the larger population
indicated that SLE has a strong genetic basis [8]. In addition,
genetic analyses of inbred murine models of systemic autoim-
munity also strongly support a genetic predisposition for
SLE susceptibility [9]. Further studies have shown that the ge-
netic basis of LN predisposition exhibits in two aspects. On
one hand, some susceptibility alleles of candidate genes are
associated with LN disease severity. On the other hand, there
exists a set of kidney-speciﬁc genes that are likely to amplify or
sensitize patients to autoimmune pathology of LN [10].
Advances in high-throughput genotyping technology and
completion of the Human Genome Project facilitate the devel-
opment of genome-wide searches for genetic polymorphisms to
SLE and LN. The availability of the entire genome sequence
has drastically changed the study of genetic predisposition of
LN during the past several years. Chromosomal regions con-
taining possible susceptibility loci can be identiﬁed by linkage
analysis based on the genetic location. Until now, many candi-
date genes of LN predisposition have been identiﬁed.
Histocompatibility complex (MHC) has been demonstrated
to be linked to lupus traits, nephritis and production of auto-
antibodies [11]. Freedman et al. reported human leukocyte
antigen (HLA)-B8 and DR2 are positively associated with
LN in patients of both African Americans (blacks) and whites
[12]. HLA-DQA and HLA-DR alleles have also been shown to
be associated with LN in an Italian population in another
study [4]. Furthermore, several studies have shown that low-
afﬁnity variants of both Fcc receptor (FccR) IIA and IIIA
are associated with SLE and LN, and FccRIIA genes are
important disease susceptibility factors for SLE, particularly
for LN, suggesting that the Fc receptor may inﬂuence clinical
manifestation of LN [13,14]. In addition, copy number varia-
tion of the rat and human Fcgr3 genes is a determinant of sus-
ceptibility to immunologically mediated glomerulonephritis,
which provides direct evidence for the importance of genome
plasticity in the evolution of genetically complex phenotypes
[15]. A meta-analysis on the V158F variant of FccRIIIA re-
vealed an increased risk of LN for individuals with two copies
of the risk allele (F/F) [16]. The FcgRIIIA-V/F158 polymor-
phism may be a susceptibility factor for SLE and LN, play
an important role in the pathogenesis of the disease and show
prognostic and therapeutic implications as well [16,17]. Thepredominant distribution of FccRIIA homozygous R/R131
genotype observed in LN patients indicated that this genotype
is a heritable risk factor for immune complex mediated renal
injury in Brazilian lupus patients [18].
Genome-wide transcriptomic analysis has uncovered differ-
ential gene expression proﬁle in murine LN. By microarray
analysis of glomerular gene expression, Teramoto et al. identi-
ﬁed 567 up-regulated genes in the glomeruli of MRL/lpr mice
with LN compared to control congenic mice. Those included
complement components, adhesion molecules, chemokines
and their receptors, and molecules related to antigen presenta-
tion [19]. Allam et al. observed a greater expression and activa-
tion of mouse double minute 2 homolog (Mdm2) gene in the
spleen and kidneys in a mouse model of lupus (MRL-Faslpr
mice) than healthy controls. Their data suggested that the
induction of Mdm2 promotes the expansion of plasma cells,
which cause autoantibody production and immune complex
disease in MRL-Faslpr mice [20]. Therefore, antagonizing
Mdm2 may have therapeutic potential in LN. Liu et al. iden-
tiﬁed kallikrein (KLK) genes that are associated with the sus-
ceptibility to anti-glomerular basement membrane (anti-GBM)
antibody-induced nephritis and LN [21]. The polymorphisms
in the promoter region of KLK genes are responsible for the
differential expression of KLK-kinin in the kidney of different
mice strains, and the higher expression of KLK plays a protec-
tive role against LN [22,23]. Another study on lupus mouse
model reported that STAT4-deﬁcient NZM mice developed
accelerated nephritis and displayed increased mortality in the
absence of high levels of anti-double-stranded DNA antibodies
(anti-dsDNA Abs) and in the presence of relatively reduced
levels of IFN-c. In contrast, STAT6-deﬁcient NZM mice
exhibited a signiﬁcant reduction in incidence of kidney disease
with a dramatic increase in survival, in the presence of high
levels of anti-dsDNA Abs. These studies indicate that STAT4
may be associated with LN [7].
In recent years, more candidate genes have been identiﬁed.
For example, the programmed cell death 1 (PDCD1 or PD1)
PD1.3A allele was reported to be a risk factor for LN in Euro-
pean descendants [6]. PDCD1 gene variation was also associ-
ated with LN and these ﬁndings conﬁrmed PDCD1 as a LN
susceptibility marker [24]. In addition, Jonsen et al. reported
that variation in the promoter of the pentraxin C-reactive pro-
tein (CRP) gene has been associated with SLE or SLE nephri-
tis in Caucasian and African ethnicities [25]. Among the LN
susceptible genes, angiotensin-converting enzyme (ACE) and
angiotensinogen (AGT) are the best illustrated renal-speciﬁc
factors. Two polymorphisms, Alu insertion/deletion (I/D)
and 23 949 (CT)2/3, in the ACE gene that were correlated with
serum ACE levels have now been associated with LN in several
studies [26,27], while the M235T polymorphism in the AGT
gene was also shown to be associated with LN in Asians
[26]. Furthermore, meta-analysis showed the ACE D allele
or DD genotype could be a predictive marker for risk of
SLE or LN. D allele and DD homozygous are signiﬁcant ge-
netic markers to predict SLE susceptibility, while DD geno-
type is a valuable marker to predict the LN risk [28].
Functional genetic polymorphisms of some cytokines and
chemokines have been identiﬁed to be correlated with LN.
For example, –2518 A/G polymorphism of inﬂammatory
mediator monocyte chemoattractant protein-1 (MCP-1) has
been shown to be associated with LN [29]. The low frequencies
of the risk alleles of the integrin alpha M (ITGAM) gene in
Table 1 Candidate genes associated with LN
Gene Full name Variation Ref
Kidney-speciﬁc targeting
FCGR3A Fc c receptor III-A V/F158 [14]
FCGR3B Fc c receptor III-B Copy number variation (CNV) [15]
ACE Angiotensin converting enzyme Alu I/D [27]
MCP-1 Monocyte chemoattractant protein-1 A–2518G [29]
AGT Angiotensinogen M235T [26]
IL-8 Interleukin-8 T–845C [31]
PAI-1 Plasminogen activator inhibitor-1 –675 4G4G indel [32]
eNOS Endothelial nitric oxide synthase Intron 4 repeat [33]
EPCR Endothelial protein C receptor A6936G [34]
Ampliﬁcation of the autoimmune pathology
CCR5 C-C chemokine receptor 5 D32 [35]
SPP1 Osteopontin C707T [36]
HLA-DQA DQ alpha DQA\0101 [4,12]
HLA-DQB DQ beta DQB\0201 [4,12]
PDCD1 Programmed cell death 1 PD1.3G/A [24]
ER Estrogen receptor PpXx [37]
MBL2 Mannose binding lectin 2 Gly54Asp [38]
UG Uteroglobin A38G [39]
IFNG IFNc Allele 114 [40]
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to disease susceptibility and probably severe manifestations of
SLE [30]. Association studies evaluate candidate genes based
on their function in the immune system or their aberrant
expression in lupus patients [10]. Some important candidate
genes associated with LN are summarized in Table 1.
Aberrations in epigenetic regulation for LN
Immune-mediated LN is multigenic and/or multifactorial in
origin. Epigenetic mechanisms get involved in a variety of
autoimmune disorders, including LN, by regulating immuno-
genicity and autoantibody production. The inﬂuence of epige-
netic mechanisms on LN has been investigated in many
studies. Epigenetic modiﬁcations can inﬂuence gene expression
and alter cellular function without modifying the genomic se-
quence. Three main epigenetic processes include DNA methyl-
ation, nucleosome repositioning by histone modiﬁcations and
miRNAs [41].
DNA methylation
Until now, DNA methylation is the most widely studied epige-
netic modiﬁcation. Usually, methylation of cytosine in the reg-
ulatory sequences of DNA is associated with transcriptional
inactivation of genes, whereas hypomethylation is related to
the activation of transcription. Many studies have indicated
correlation of DNA methylation with the pathogenesis of
SLE. Hypomethylated state of genes in T and B lymphocytes
has been generally observed in SLE patients [41,42]. For in-
stance, the lymphocytes from SLE patients displayed gene
hypomethylation when compared to normal controls. Studies
using demethylating agents indicate that DNA hypomethyla-
tion plays a pathophysiological role in SLE and LN. The
hypomethylated state and demethylated DNA fragments in
the serum of SLE patients can induce the production of anti-
DNA antibodies, which are involved in the pathophysiology
of SLE and LN [41,43].The degree of hypomethylation was thought to be correlated
with lupus disease activity. Numerous methylation-sensitive
genes are over-expressed in lupus CD4+ T cells. Also, CD8+
T lymphocyte and NK cell speciﬁc perforin (PRF1) was over-
expressed due to hypomethylation modiﬁcation of DNA in
SLE patients [44] and overexpression of serine/threonine protein
phosphatase gene PP2A was reported in SLE patients [45]. Wen
et al. reported hypomethylation was crucial for apoptotic DNA
to induce SLE-like autoimmune disease in SLE-non-susceptible
mice by producing high levels of anti-dsDNA Abs, proteinuria
and glomerulonephritis [46]. Reduced CD5 expression caused
by hypomethylation of an intracellularly expressed truncated
CD5 variant (CD5-E1B) on the surface of B lymphocytes pro-
motes auto-reactivity in SLE [47]. The involvement of DNA
methylation in X chromosome provides a potential explanation
for the female predominance in SLE [47]. In CD4+ T cells of fe-
male SLE patients, demethylation with 5-azacytidine results in
overexpression of the CD40 ligand, which is a B lymphocyte
co-stimulatory molecule encoded on the X chromosome. How-
ever, hypomethylation is not associated with SLE for male SLE
patients due to the fact that the male X chromosome is demethy-
lated under physiological conditions [48].
Histone modiﬁcations
The histone octamer consists of two copies of each of the his-
tone proteins H2A, H2B, H3 and H4. Histone complexes pos-
sess ﬂexible N terminal tails that are accessible to
posttranslational modiﬁcations and can strongly impact the
functional capacities of nucleosomes [41]. Histone modiﬁca-
tion patterns in SLE are complicated. Firstly, systemic inﬂam-
mation activates a systemic immune response, and
subsequently causes apoptosis or death of lymphocytes, which
drives the release of nuclear particles. Nucleosomes released
from apoptotic cells cannot be cleared sufﬁciently, which leads
to the accumulation of excessive amount of chromatin debris
(DNA, histones and nucleosomes) in the circulation and tis-
sues [49]. Autoreactive B cells can further be activated by tak-
ing up the released nuclear particles and differentiate into
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immune complex formation and causes glomerulonephritis in
the kidney [49]. During LN inﬂammatory reaction process, his-
tone modiﬁcation often occurs. Histone acetylation in some re-
gions is associated with disease activity. For example,
acetylated histone H4, H2A and H2B become autoantibody
targets in lupus [50]. On the other hand, histone acetylation
in other regions seems to have protective effects [51]. Adminis-
tration of histone deacetylase (HDAC) inhibitors led to re-
duced IL-6, IL-10, IL-12 and IFN-c in splenocytes and
improved glomerulonephritis in MRL-lpr/lpr mice [51]. His-
tone hyperacetylation has also been shown to be associated
with the progression of SLE. Histone deacetylase sirtuin-1
(Sirt1) was over-expressed in MRL/lpr CD4+ T lymphocytes.
HDAC-treated cells contained autoantigens, which responded
to SLE-derived autoantibodies [52]. Hyperacetylation of genes
related to apoptosis or cell cycle regulation plays a role in SLE
and LN [52]. In addition, genome-wide acetylation of histones
seems to improve the symptoms in lupus-prone mice while
hyperacetylation of various genetic loci in human SLE is asso-
ciated with disease severity [53].
MicroRNAs
miRNAs are short non-coding RNA sequences that regulate
gene expression by blocking protein translation or inducing
mRNA degradation. The variation in miRNAs could cause
the dysregulation of a broad range of targeting genes, which
are associated with diseases. Therefore, miRNAs could be good
biomarkers for autoimmune diseases [54]. The circulating miR-
NAs are systematically altered in SLE even LN [54]. The varied
expression of miRNAs in kidney during pathological processes
makes miRNAs a valuable new tool for understanding, diagnos-
ing, and discovering therapeutic options for SLE and LN.
Dai et al. compared miRNA expression in renal biopsies of
LN patients with normal controls by microarray technology
and identiﬁed 30 down-regulated and 36 up-regulated miR-
NAs. These differentially expressed miRNAs may be potential
diagnosis biomarkers to illuminate pathogenic mechanisms in
LN [55]. Increased expression was detected for miR-142-3p
and miR-181a in SLE patients, while expression of miR-
106a, miR-17, miR-20a, miR-92a and miR-203 was decreased.
Moreover, expression of miR-343-3p, miR-223 and miR-20a
was signiﬁcantly low in SLE patients with LN [54]. Compared
to healthy controls, expression of miR-638, miR-198 and miR-
146a was signiﬁcantly different in LN patients [56]. Further-
more, the degree of change in glomerular miR-146a and
tubulointerstitial miR-638 expression was correlated with clin-
ical disease severity, suggesting that these miRNA targets may
play a role in the pathogenesis of LN [56]. miR-371, miR-423,
miR-1224, miR-663 and miR-638 were reported to be differen-
tially expressed in LN across different racial groups. Among
them, miR-371, miR-1224 and miR-423 were the ﬁrst to be re-
ported to be associated with LN [57]. Additionally, expression
of miR-221 and miR-222 in urinary sediment was associated
with LN disease activity and may also serve as biomarkers [58].
Proﬁling protein biomarkers in LN
The differential expression of protein biomarkers in serum and
urine of SLE patients may reﬂect the pathophysiological statusof disease development and therefore may be used as biomark-
ers for early diagnosis and prognosis. Common protein mark-
ers include antigens, autoantibodies and cytokines, etc.Serum protein markers for LN
Autoimmune serology markers of SLE include anti-dsDNA
antibodies, anti-C1q antibodies and complement C3 and C4
levels. Anti-dsDNA antibodies, ﬁrst detected and measured
55 years ago, are the best studied of all autoantibodies found
in SLE and are still ubiquitously used to help diagnose and
manage this disease, because the level of this autoantibody is
correlated with disease activity [59]. In addition, nucleosomes
play a pivotal role in the development of kidney lesions by
mediating the production and binding of autoantibodies to ba-
sal membranes [60]. Meta-analysis showed that anti-nucleo-
some antibodies are a highly accurate diagnostic marker for
SLE and LN [61]. In addition, serum anti-C1q antibody is also
a valuable noninvasive biological marker for prediction of
renal histopathology in LN. The level of serum anti-C1q
antibody can be used as a marker for LN activity with higher
sensitivity and speciﬁcity than traditional markers of dis-
ease activity, such as C3/C4 consumption and anti-dsDNA
[62].
Large-scale screening of the disease biomarkers using high
throughput autoantigen microarray has facilitated the discov-
ery of disease biomarkers at the global level. By using a glo-
merular proteome array, Li et al. identiﬁed autoantibody
clusters that best predict the disease activities of SLE and
LN [63]. Some of the autoantibody clusters, such as anti-chro-
matin, anti-DNA, anti-Ro and anti-RNP, were associated well
with disease activity in SLE and incomplete lupus (ILE) [64].
They found that presence of IgM autoantibodies in patient’s
sera was associated with reduced LN severity [63,64]. These
studies veriﬁed proteomic microarray as a powerful tool for
uncovering novel autoantibody biomarkers for autoimmune
diseases.
In recent years, some novel serum biomarkers for LN have
been identiﬁed. For instance, serum a proliferation-inducing li-
gand (APRIL) as well as its intrarenal mRNA levels were re-
ported to be associated with resistance to treatment,
indicating that APRIL could be a potential biomarker for pre-
dicting difﬁcult-to-treat cases of LN [65]. Panda et al. reported
that higher and intermediate mannose binding lectin (MBL)
levels are signiﬁcantly associated with nephritis in SLE patients
[66]. Since serum cystatin C is a good marker for renal func-
tion, the serum b2 microglobulin/cystatin C (Sb2 M/SCysC)
index could be a better indicator of renal activity in SLE
[67]. In addition, serum complement factor H (CFH) levels
are also associated with disease activity of LN [68]. Serum lev-
els of soluble interleukin 7 receptor (sIL-7R) are strongly aug-
mented in patients with LN, thus it may be a marker of SLE
disease, especially nephritis [69]. A cross-sectional study
including 20 patients suggested that vanin-1 level in peripheral
blood may be a promissory biomarker for LN and warrants
further validation in a larger cohort [70]. Other cytokines
and chemokines have been proved to be associated with LN,
including VEGF [71] and higher levels of IL-18 and IFNc
[72]. Increased levels of macrophage inﬂammatory protein-1a
(CCL3), MCP-1, RANTES and IFNc-induced protein-10 are
also observed in the serum of SLE patients [73].
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Generally, urinary substances are likely to reﬂect kidney dam-
age better than serum components. Urine is a source of bio-
ﬂuid which is easy to harvest and the biomarkers in urine
are usually reﬂecting the renal function directly in various
kinds of nephritic diseases. Proteomic approaches, such as
two-dimensional gel electrophoresis, mass spectrometric and/
or immunochemical identiﬁcation of proteins, surface-
enhanced laser desorption/ionization time-of-ﬂight mass spec-
trometry (SELDI-TOF-MS) and capillary electrophoresis-MS,
have been used to screen potential urine biomarkers that are
associated with renal damages caused by LN [74]. The usual
markers of renal disease include urinary protein, creatinine,
etc., although the currently recommended spot urinary protein
to creatinine ratio may not be sufﬁciently sensitive to detect
early nephritis. Urinary biomarker candidates include adhe-
sion molecules, cytokines, chemokines and their receptors
[74]. The urinary proteome proﬁles of 129/Sv and DBA/1 mice
that developed severe immune-mediated nephritis are signiﬁ-
cantly different from those of B6 and BALB/c mice [75]. For
example, levels of vascular cell adhesion molecule 1 (VCAM-
1), P-selectin, tumor necrosis factor receptor 1 (TNFR1) and
CXCL16 were higher in the 129/Sv and DBA/1 strains, which
were highly susceptible to severe immune-mediated glomerulo-
nephritis. Another pilot study showed that transferrin,
a1-acid-glycoprotein (AGP) and lipocalin-type prostaglandin
D-synthetase (L-PDGS) may serve as potential biomarkers
for impending nephritis ﬂares in pediatric lupus [76].Table 2 Summary of protein markers associated with LN
Protein Full name
Serum protein markers
C3 Complement c
C4 Complement c
Anti-dsDNA Abs Anti-double st
Anti-C1q Abs Anti-complem
ESR Erythrocyte se
CRP C-reactive pro
APRIL A proliferation
MBL Mannose bind
Sb2M/SCysC Serum b2 micr
CFH Complement f
sIL-7R Soluble interle
VEGF Vascular endo
IL-18 Interleukin-18
IFNc Gamma interf
CCL3 Macrophage in
MCP-1 Monocyte che
CCL5 Chemokine (C
IP-10 IFNc-induced
VNN1 Vanin-1
Urinary protein markers
VCAM-1 Vascular cell a
TNFR1 Tumor necros
CXCL16 Chemokine (C
AGP a1-acid-glycop
L-PDGS Lipocalin-type
MCP-1 Monocyte che
FLCs Free light chai
TWEAK Tumor necrosMore new urinary biomarkers have been reported. For
example, urinary VCAM-1 level is associated with nephritis
activity in SLE patients [77]. In addition, baseline mean uri-
nary MCP-1 levels were signiﬁcantly correlated with both
LN class and severity of LN ﬂare, hence, the high speciﬁcity
makes urinary MCP-1 become a non-invasive marker for
determining lupus ﬂare and LN class [78]. Moreover, urinary
free light chains (FLCs) are potentially useful biomarkers in
International Society of Nephrology and Renal Pathology
Society (ISN/RPS) class III/IV LN or proliferative LN [79].
Furthermore, urinary tumor necrosis factor-like weak inducer
of apoptosis (TWEAK) levels were correlated with all active
indexes of LN, suggesting its potential role as a novel bio-
marker of active LN [80]. Based on these studies, we summa-
rized the protein markers in Table 2.
Conclusion
Over the last decade, omics-based techniques have been exten-
sively utilized for biomarker screening at the level of genetics,
epigenetics and proteomics. Reviewing the current list of best
validated LN disease susceptibility candidate genes and the po-
tential functional interaction of these genes may allow us to
elucidate the genetic basis of LN predisposition. The effect
of epigenetic regulation on LN pathology may also play an
important role in the pathogenesis of LN. The variations at
the genetic and epigenetic level as well as the environmental
factors may work together to drive the pathogenesis of LN.
The appearance and variation of protein biomarkers in serumRef
omponent 3 [81]
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Li Y et al / Biomarkers for Lupus Nephritis 163and urine of patients may reﬂect the pathophysiological status
of disease development and therefore may be used as biomark-
ers for monitoring disease activity of LN.
As more emerging novel technologies, such as next-genera-
tion sequencing and high throughput proteomic arrays, are
being widely employed in biomarker screening, we are expect-
ing more and more biomarkers associated with lupus nephritis
will be discovered. Elucidating the underlining molecular
mechanisms between the biomarker dysregulation and disease
phenotype will lead us to identify potential therapeutic targets
for treatment of LN, and also to establish better tools for pre-
diction, early diagnosis and prognosis of lupus nephritis.
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